S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 10.9 CNY 0.18% Market Closed
Market Cap: 7.2B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Gross Margin
Shandong Sinobioway Biomedicine Co Ltd

78.9%
Current
78%
Average
23.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.9%
=
Gross Profit
340.3m
/
Revenue
431.4m

Gross Margin Across Competitors

Country CN
Market Cap 7.2B CNY
Gross Margin
79%
Country ZA
Market Cap 51.9B Zac
Gross Margin
50%
Country DE
Market Cap 38.1B EUR
Gross Margin
25%
Country IN
Market Cap 1.5T INR
Gross Margin
54%
Country CN
Market Cap 119.4B CNY
Gross Margin
31%
Country ZA
Market Cap 12.2B Zac
Gross Margin
23%
Country IN
Market Cap 671.2B INR
Gross Margin
38%
Country JP
Market Cap 1.1T JPY
Gross Margin
27%
Country JP
Market Cap 6.5B EUR
Gross Margin
27%
Country FR
Market Cap 5.3B EUR
Gross Margin
20%
Country JP
Market Cap 4.4B EUR
Gross Margin
23%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7.2B CNY
Industry
Chemicals

In the bustling world of biotechnology, Shandong Sinobioway Biomedicine Co Ltd stands as a dynamic player, deeply embedded in the heart of China's burgeoning pharmaceutical and biotech sector. Founded with a vision to harness the power of biology for transformative impacts, the company has charted a remarkable journey rooted in innovation and robust research capabilities. Sinobioway primarily delves into the development and commercialization of biological products, focusing on vaccines, antibodies, and other biopharmaceuticals. By emphasizing advanced biotechnologies, the company creates life-enhancing solutions, addressing both common and complex health challenges. Its strategic approach involves a blend of cutting-edge research, partnerships with academic institutions, and collaborations with global pharmaceutical giants, paving the way for market-leading products. Revenue streams for Sinobioway are predominantly driven by its diverse product portfolio that caters to a wide array of medical needs. Through comprehensive R&D, they've effectively commandeered a niche within the preventive medicine sector, particularly with their vaccines, which are in high demand due to increasing health awareness and governmental health initiatives. Additionally, the company fortifies its financial foundation through licensing deals, tapping into global markets and establishing a significant presence internationally. By strategically optimizing production processes and deploying an efficient distribution network, Sinobioway ensures its biomedicine products reach various demographics, thereby anchoring its position in the bioscience industry while continually seeking growth and expansion opportunities beyond local confines.

Intrinsic Value
3.11 CNY
Overvaluation 72%
Intrinsic Value
Price
S
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.9%
=
Gross Profit
340.3m
/
Revenue
431.4m
What is the Gross Margin of Shandong Sinobioway Biomedicine Co Ltd?

Based on Shandong Sinobioway Biomedicine Co Ltd's most recent financial statements, the company has Gross Margin of 78.9%.